Target intelligence / Profile preview

Argonaute 2 / RNA-induced silencing complex (AGO2/RISC)

Target
AGO2/RISC
Molecular classification
Enzyme, Ribonuclease, Endonuclease, RNA-binding protein
01

Overview

Argonaute 2 (AGO2) is the core catalytic component of the RNA-induced silencing complex (RISC), a multiprotein ribonucleoprotein complex responsible for post-transcriptional gene silencing via RNA interference (RNAi). Guided by small non-coding RNAs, such as microRNAs (miRNAs) or small interfering RNAs (siRNAs), AGO2 acts as an endonuclease (Slicer) that directly cleaves target messenger RNAs (mRNAs) with high complementarity, or represses translation when complementarity is partial. AGO2 is highly implicated in various human pathologies, particularly in oncology, where its overexpression promotes tumor growth, metastasis, and angiogenesis, and suppresses antitumor immunity. It also plays roles in viral infections, neurodegenerative diseases, and cardiovascular disorders. Therapeutic strategies targeting AGO2/RISC include small-molecule inhibitors (e.g., BCI-137, acriflavine, and aurintricarboxylic acid) that block miRNA loading or disrupt RISC assembly, as well as antisense oligonucleotides (e.g., miravirsen) that prevent miRNA-AGO2 interactions. Conversely, the AGO2/RISC machinery is also harnessed by therapeutic siRNAs to achieve targeted gene knockdown.

Other names
AGO2EIF2C2Argonaute-2Protein argonaute-2Eukaryotic translation initiation factor 2C 2RISCRNA-induced silencing complexSlicer
02

Biological functions

Gene silencingRNA interferenceTranslation repressionmRNA cleavagemiRNA processing
03

Disease associations

CancerInfectionCardiovascular diseaseNeurodegenerative diseaseErectile dysfunction
04

Safety considerations

Off-target gene silencingDisruption of endogenous miRNA pathwaysSystemic toxicity due to essential role in development and homeostasisPotential for triggering innate immune responses
05

Interacting drugs

BCI-137

5 more in the full profile.

06

Biomarkers

AGO2 expression levelInterferon signaturemiRNA expression profilemiR-122 levels

Beyond the preview

Go deeper on Argonaute 2 / RNA-induced silencing complex (AGO2/RISC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Argonaute 2 / RNA-induced silencing complex (AGO2/RISC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call